财务业绩发布后，公司将于美国东部时间2026年2月26日(星期四)上午八时正(即香港时间2026年2月26日 (星期四)下午九时正)举行电话会议。 格隆汇2月11日丨百济神州(06160.HK)公告，公司将于2026年2月26日(星期四)(即香港联交所交易时间 后)报告其根据美国公认会计原则及美国证券交易委员会适用规则编制的2025年第四季度及全年的财务 业绩。公司董事会将于2026年2月26日(香港时间)审阅及批准2025年第四季度及全年的财务业绩。 ...

財務業績發佈後，本公司將於美國東部時間2026年2月26日（星期四）上午八時正 （即香港時間2026年2月26日（星期四）下午九時正）舉行電話會議。 電話會議將以網路直播方式進行，網絡直播鏈接可從本公司網站的投資者關係頁 面訪問，網址為 https://ir.beonemedicines.com 。為確保及時連接，建議與會者在預 定的網絡直播前至少15分鐘進行註冊。本公司網站將提供業績電話會議網絡直播 的存檔回放。 本公司另將於2026年3月31日或之前公佈其根據香港聯合交易所有限公司證券 上市規則（「香港上市規則」）編製的截至2025年12月31日止年度的經審核財務業 績，此全年業績預計將與根據美國公認會計原則和美國證券交易委員會適用規則 編製的年度業績相同，但香港上市規則所要求的指定附加資料以及將本公司的年 度業績從美國公認會計原則與國際財務報表準則進行核對的結果除外。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines ...

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report highlights significant advancements in the pharmaceutical industry, particularly in the development and approval of innovative drugs, with a focus on oncology and immunotherapy [5][6][10]. Summary by Sections 1. Latest Policy Updates - The National Medical Products Administration (NMPA) has issued several key announcements, including guidelines to strengthen the supervision of entrusted drug production and the release of the 2025 Clinical Application Guidelines for Antitumor Drugs [10][15][18]. - New regulations aim to support the development of innovative drugs and ensure the quality and safety of pharmaceuticals through enhanced management practices [11][12][14]. 2. Domestic New Drug Approvals - In January 2026, a total of 172 new drugs were approved for clinical trials, a decrease of 55 from the previous month. Among these, 78 were chemical drugs, 88 were biological products, and 6 were traditional Chinese medicines [22][23]. - The majority of new drug approvals were in the fields of oncology and immune modulation, accounting for 53% of the total [22]. 3. Global Innovative Drug Development - The report lists several drugs that have shown positive clinical results, including Neumora Therapeutics' NMRA-511 and GSK's new hepatitis B drug, which achieved success in phase 3 studies [6][10]. - Notable approvals include the BCL-2 inhibitor from BeiGene, which received dual indications for chronic lymphocytic leukemia and mantle cell lymphoma [40][41]. 4. New Drug Listings - The report details new drug listings, including the approval of the combination drug for ADHD treatment by Aikobai, which has shown significant efficacy in clinical trials [41][43]. - The approval of Merck's drug for pulmonary arterial hypertension represents a new treatment option that addresses the underlying causes of the disease rather than just symptomatic relief [40].

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Group 1 - The core viewpoint of the news is that BeiGene's stock has increased by 5.08%, reaching a price of 291.00 CNY per share, with a trading volume of 5.91 billion CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 448.34 billion CNY [1] - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is primarily engaged in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of fund holdings, one fund under Huatai-PineBridge has a significant position in BeiGene, holding 16,700 shares, which accounts for 2.36% of the fund's net value, making it the seventh-largest holding [2] - The Sci-Tech Innovation Index (588880) has reduced its holdings by 3,149 shares in the fourth quarter, with a current estimated floating profit of approximately 235,600 CNY [2] - The Sci-Tech Innovation Index fund, established on November 8, 2023, has a latest scale of 191 million CNY, with a year-to-date return of 11.76% and a one-year return of 62.02%, ranking 357 out of 4,295 in its category [2]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Group 1 - Major blue-chip stocks mostly rose, with HSBC Holdings closing at HKD 141.801, up 1.8% from the previous close [2] - Tencent Holdings closed at HKD 561.139, reflecting a 0.2% increase from the previous close [2] Group 2 - Tencent Holdings (00700) latest price is HKD 560.000, with an increase of HKD 12.500 or 2.28% [3] - Alibaba Group (09988) latest price is HKD 157.900, up HKD 2.900 or 1.87% [3] - HSBC Holdings (00005) latest price is HKD 139.300, up HKD 4.500 or 3.34% [3] - AIA Group (01299) latest price is HKD 86.350, up HKD 2.850 or 3.41% [3] - Meituan (03690) latest price is HKD 91.050, down HKD 0.350 or 0.38% [3] - China Ping An (02318) latest price is HKD 73.000, up HKD 3.400 or 4.89% [3] - Hong Kong Exchanges (00388) latest price is HKD 418.600, up HKD 11.000 or 2.70% [3] - Baidu Group (09888) latest price is HKD 142.200, up HKD 4.400 or 3.19% [3] - Kuaishou Technology (01024) latest price is HKD 69.300, down HKD 1.950 or 2.74% [3]

Summary of Key Points Core Viewpoint - The company disclosed that as of September 30, 2025, it had a total of 36,172 registered shareholders, which includes 36,008 shareholders of RMB shares, 41 shareholders registered in the Hong Kong stock register, and 115 shareholders in the Swiss stock register [1]. Group 1 - The company reported that there are 36,164 registered shareholders of ordinary shares, which includes 36,008 RMB shares and 164 from other regions [1]. - The total number of registered holders of American Depositary Shares (ADS) is 8, contributing to the overall count of 36,172 [1]. - The company noted that the reported numbers do not include beneficial owners represented by brokers for ordinary shares and ADS held by agents [1].

Group 1 - The Hong Kong stock market showed a strong opening on February 9, with the Hang Seng Index rising by 1.59%, the State-owned Enterprises Index increasing by 1.54%, and the Technology Index up by 1.9% [1] - The Hang Seng Biotechnology Index, focusing on innovative drugs, performed robustly, with the largest ETF tracking this index (159892) rising nearly 2% [1] - The innovative drug sector is expected to enter a profit realization acceleration phase by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceuticals turning losses into profits, while companies like 3SBio are significantly increasing their performance [1] Group 2 - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth [1] - External collaborations, such as business development (BD) partnerships, are becoming important drivers for enhancing performance in the innovative drug sector [1] - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, covering numerous innovative targets like BeiGene and Innovent Biologics, and is expected to continue its valuation recovery trend under catalysts like overseas expansion of innovative drugs and commercial insurance directories [1]

Core Viewpoint - The Hong Kong stock market, particularly the technology sector, is experiencing significant capital inflows despite global risk asset volatility, indicating a potential rebound in the sector's performance [1][2]. Group 1: Capital Inflows - Southbound funds recorded a net inflow of HKD 561 billion (approximately USD 498 million) last week, showing a marked increase compared to the previous week [2]. - Technology ETFs linked to Hong Kong stocks saw a total net inflow of HKD 173.59 billion last week, suggesting strong investor interest [4]. - Foreign capital also flowed into Hong Kong stocks, with a net inflow of USD 1.88 billion as of February 4, down from USD 2.8 billion the previous week, but still maintaining a relatively high level [4]. Group 2: Valuation and Performance - The price-to-earnings (P/E) ratio of the Hong Kong technology index tracked by the Hong Kong Stock Connect Technology ETF is approximately 26 times, which is significantly lower than the A-share ChiNext index (around 42 times) and the US Nasdaq index (around 37 times) [5]. - Since January 2017, the Hong Kong Stock Connect Technology Index has increased by 153.72%, outperforming the Hong Kong Internet Index (0.99%) and the Hang Seng Technology Index (45.74%) [6]. - Analysts suggest that the current valuation levels in the Hong Kong market remain attractive, with key investment opportunities likely to focus on sectors such as technology innovation and new productivity [6].